title: Flow cytometric MRD detection in selected mature B-cell malignancies.
abstract: The quantification of submicroscopic minimal residual disease (MRD) after therapy proved to have independent prognostic significance in many mature B-cell malignancies. With the advent of routine bench-top cytometers capable of simultaneously analyzing ≥ 4 colors and with improved standardization, flow cytometry has become the method of choice for MRD assessments in some lymphoma entities. Herein we describe general aspects of flow cytometric standardization. Using chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) as examples we explain in detail the application of flow cytometry for MRD detection.
authors.affiliation: Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany. s.boettcher@med2.uni-kiel.de
authors.forename: Sebastian
authors.initials: S
authors.lastname: Böttcher
authors.forename: Matthias
authors.initials: M
authors.lastname: Ritgen
authors.forename: Michael
authors.initials: M
authors.lastname: Kneba
mesh_terms: D001854:Bone Marrow Cells / Q000473:pathology; D005434:Flow Cytometry / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology*; D007963:Leukocytes, Mononuclear / Q000473:pathology; D008027:Light; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000473:pathology*; D018365:Neoplasm, Residual / Q000175:diagnosis*; D016133:Polymerase Chain Reaction; D012015:Reference Standards; D012542:Scattering, Radiation; D013194:Staining and Labeling